Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy

Commentary
Video

The founding president and chief executive officer of Parent Project Muscular Dystrophy discussed recent and upcoming milestones in the field.

“There's no broadly applicable treatment at this moment to address dystrophin production. We have 4 approvals of antisense oligonucleotides that really only apply to around 20% of the population... The access issues are difficult for us... we've had some negative payer policies and those are likely to inhibit access for certain people, which isreally heartbreaking for all of us because we are very anxious for all of these boys to have treatment ensured.”

While 2023 has seen lots of progress in the treatment landscape of the field, including the summer approval of delandistrogenemoxeparvovec (marketed as Elevidys by Sarepta), the field’s first gene therapy, more work always remains to be done. September is Duchenne Action and Muscular Dystrophy Awareness Month, and CGTLive is speaking with clinicians and advocacy groups in the space to learn more about the progress in the field to date and unmet needs that remain.

CGTLive spoke with Pat Furlong, BSN, RN, founding president and chief executive officer, Parent Project Muscular Dystrophy (PPMD), to learn more about her thoughts on the progress to date in the field of muscular dystrophies. She lauded the first-of-its-kind FDA approval of Elevidys and touched on other disease-modifying therapies (DMTs) available for Duchenne Muscular dystrophy (DMD) but stressed that most of the patient population of DMD still lack DMTs, and even for patients indicated for DMTs, many factors get in the way of actually accessing these therapies. She also shared milestones she is looking forward to in the field, such as PDUFA dates for other modes of therapy, including vamorolone and givinostat.

REFERENCE
Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne muscular dystrophy. News release. Sarepta Therapeutics. June 22, 2023. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-elevidys-first-gene
Related Videos
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
M. Peter Marinkovich, MD, on Bringing RDEB Treatment to the Local Level
Caspian Oliai, MD, MS, the medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Frederick “Eric” Arnold, PhD
Genovefa (Zenia) Papanicolaou, MD, an infectious diseases specialist at Memorial Sloan Kettering Cancer Center
Jeffrey Chamberlain, PhD, on Exciting New Research at MDA 2024
Alan Beggs, PhD, on Challenges in Therapeutic Development for Rare Diseases
Akshay Sharma, MBBS, a bone marrow transplant physician at St. Jude Children’s Research Hospital
PJ Brooks, PhD
John DiPersio, MD, PhD, the director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine
© 2024 MJH Life Sciences

All rights reserved.